Home
Charts
Search
Watchlist
Products
All IPOs
₹128 - 128
Curis Lifesciences Ltd
PharmaceuticalsIPOSME
₹128 - 128
Curis Lifesciences is the pharma manufacturer, specializing in manufacturing of a wide range of pharmaceutical products such as Tablets, Capsules, External Preparations, Oral Liquid, Sterile Ophthalmic Ointments. We operate in global as well as domestic markets. We undertake manufacturing activities on loan license, Contract Manufacturing and Direct Export basis/Own Brand Marketing basis. In terms of the nature of manufacturing and business activities,
Lot1,000Min Invest₹2,56,000Face Value₹10Issue Size₹28 CrFresh Issue₹28 CrListing Price₹146CMP₹176
Timeline
7 Nov
Bidding opens
11 Nov
Bidding closes
12 Nov
Allotment
13 Nov
Refund & demat credit
14 Nov
Listing
Subscription
Subscription opens once dates are announced
Reports
Offer Details
Terms
Issue Size₹28 Cr0.21 Cr shares
Fresh Issue₹28 Cr
Face Value₹10
Lot Size1,000 shares
ReservationQIB 49.85% · NII 15.09% · RETAIL 35.06%
Application Sizes
Retail₹2,56,0001-1 lots
sNII₹2,56,000from 2 lots
bNII₹10,24,000from 8 lots
Managers & Registrar
Lead ManagerFinaax Capital Advisors Private Limited
RegistrarMUFG Intime India Pvt Ltd
Ownership & Proceeds
Shareholding
CategoryPre IPOPost IPOPromoter Group92.68%68.04%Public7.32%31.96%
Objects of the Issue
- Funding capital expenditure towards improvement of its existing mfg facility at
- Repayment of secured loans outstanding in the name of company
- Products registrations in other countries
- Funding its working capital requirements
- General corporate purposes
Financials
Profit & Loss
| Financial Year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| RevenueCr | 24 | 35 | 36 | 50 | 61 |
| Operating ProfitCr | 4 | 3 | 8 | 11 | 11 |
| OPM% | 15.1 | 9.2 | 23.7 | 21.4 | 18.4 |
| PBTCr | 1 | 2 | 7 | 9 | 10 |
| PATCr | 0 | 1 | 5 | 6 | 7 |
| EPS | 10 | 25 | 107 | 34 | 10 |
Balance Sheet
| Financial Year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Equity CapitalCr | 1 | 1 | 1 | 6 | 8 |
| ReservesCr | -1 | 0 | 5 | 11 | 39 |
| BorrowingsCr | 18 | 16 | 17 | 16 | 22 |
| Total AssetsCr | 27 | 30 | 34 | 43 | 82 |
Cash Flow
| Financial Year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Operating Cash FlowCr | 5 | 3 | 0 | -2 | -16 |
| Investing Cash FlowCr | 0 | -1 | 0 | 0 | -2 |
| Financing Cash FlowCr | -5 | -3 | 0 | 2 | 21 |
| Net Cash FlowCr | 0 | 0 | 0 | 0 | 3 |
Strengths & Risks
Strengths · as stated in the DRHP
- Experienced Promoters and Management Team.
- Wide range of Products.
- Strategic Location of Manufacturing Facility.
- Scalable Business Model.
- Quality assurance.
Strategies · as stated in the DRHP
- Improve global presence.
- Leveraging our market skills and relationship.
- Maintaining edge over competitors.
- Customer Satisfaction.
Risks · as stated in the DRHP
- Our manufacturing facility is concentrated in Sanand, Ahmedabad, Gujarat, exposing us to risks from economic, regulatory, political, and other regional changes, including natural disasters, which could negatively impact our business operations, financial performance, and overall condition.
- As a pharmaceutical company, we operate in a highly regulated industry where our business relies on obtaining approvals from relevant regulatory and health authorities. Delays or failures in securing or renewing these essential approvals, registrations, or changes in the regulatory environment for marketing our products in regulated markets could have a significant impact on our business and strategy, ultimately affecting our overall profitability.
- Our business operations are subject to fluctuations in raw material prices.
- The company relies on a limited number of customers for its sales, and the loss of any major customer could adversely impact our revenue and profitability.
- The company relies on a limited number of suppliers for product procurement, and the loss of any key supplier could impact our business operations.
- We depend on a limited number of States for a significant portion of our revenue from operations. The loss of any of our major customer in this States due to any adverse development or significant reduction in business from our major customer may adversely affect our business, financial condition, results of operations and future prospects.